Bright Green Corporation Announces the next steps for the completion of its restructuring plan
Bright Green (OTC: BGXX) has announced key steps in its restructuring plan, with CEO Lynn Stockwell requesting court approval for the RSA Restructuring Security Agreement. The plan ensures full payment to creditors while protecting existing shareholders from dilution.
Stockwell, who manages several NASDAQ-listed DMAA Special Purpose Acquisition Corporations, aims to raise over $2 billion for pharmaceutical acquisitions. The company's strategy focuses on becoming a pioneer in U.S.-based production of plant-based legal controlled substances for medical purposes, targeting a $100 billion addressable market.
The business plan includes a $3.5 billion investment for DEA and FDA-compliant mega farms, supported by federal loan guarantees for owner/operators. Revenue streams will come from controlled substance supply contracts and the BGXX EB-5 investment program, which could generate capital through $800,000 investments from qualified applicants seeking U.S. green cards.
Bright Green (OTC: BGXX) ha annunciato passi fondamentali nel suo piano di ristrutturazione, con il CEO Lynn Stockwell che richiede l'approvazione del tribunale per l'Accordo di Sicurezza per la Ristrutturazione RSA. Il piano garantisce il pagamento completo ai creditori, proteggendo al contempo gli azionisti esistenti dalla diluizione.
Stockwell, che gestisce diverse Società di Acquisizione per Scopi Speciali DMAA quotate al NASDAQ, mira a raccogliere oltre 2 miliardi di dollari per acquisizioni farmaceutiche. La strategia dell'azienda si concentra sul diventare pioniera nella produzione negli Stati Uniti di sostanze controllate legali a base vegetale per scopi medici, mirando a un mercato indirizzabile di 100 miliardi di dollari.
Il piano aziendale include un investimento di 3,5 miliardi di dollari per mega fattorie conformi alla DEA e alla FDA, supportato da garanzie di prestito federali per i proprietari/operatori. I flussi di entrate proverranno da contratti di fornitura di sostanze controllate e dal programma di investimento BGXX EB-5, che potrebbe generare capitale attraverso investimenti di 800.000 dollari da parte di richiedenti qualificati in cerca di carte verdi statunitensi.
Bright Green (OTC: BGXX) ha anunciado pasos clave en su plan de reestructuración, con el CEO Lynn Stockwell solicitando la aprobación del tribunal para el Acuerdo de Seguridad de Reestructuración RSA. El plan asegura el pago completo a los acreedores mientras protege a los accionistas existentes de la dilución.
Stockwell, que gestiona varias Corporaciones de Adquisición de Propósito Especial DMAA que cotizan en NASDAQ, tiene como objetivo recaudar más de 2 mil millones de dólares para adquisiciones farmacéuticas. La estrategia de la empresa se centra en convertirse en pionera en la producción en EE. UU. de sustancias controladas legales a base de plantas para fines médicos, apuntando a un mercado direccionable de 100 mil millones de dólares.
El plan de negocios incluye una inversión de 3.5 mil millones de dólares para mega granjas en cumplimiento con la DEA y la FDA, respaldado por garantías de préstamos federales para propietarios/operadores. Los flujos de ingresos provendrán de contratos de suministro de sustancias controladas y del programa de inversión BGXX EB-5, que podría generar capital a través de inversiones de 800,000 dólares de solicitantes calificados que buscan tarjetas verdes de EE. UU.
Bright Green (OTC: BGXX)는 CEO Lynn Stockwell이 RSA 재구성 보안 계약에 대한 법원 승인을 요청하며 재구성 계획의 핵심 단계를 발표했습니다. 이 계획은 기존 주주를 희석으로부터 보호하면서 채권자에게 전액 지급을 보장합니다.
Stockwell은 NASDAQ에 상장된 여러 DMAA 특별목적 인수법인을 관리하며, 제약 인수를 위해 20억 달러 이상을 모금할 계획입니다. 회사의 전략은 미국 내에서 의료 목적으로 식물 기반의 합법적인 통제 물질 생산의 선구자가 되는 데 중점을 두고 있으며, 1,000억 달러의 시장을 목표로 하고 있습니다.
사업 계획에는 DEA 및 FDA 준수를 위한 35억 달러의 투자와 소유자/운영자를 위한 연방 대출 보증이 포함되어 있습니다. 수익원은 통제 물질 공급 계약과 BGXX EB-5 투자 프로그램에서 발생하며, 이는 미국 영주권을 원하는 자격 있는 지원자로부터 80만 달러의 투자를 통해 자본을 생성할 수 있습니다.
Bright Green (OTC: BGXX) a annoncé des étapes clés dans son plan de restructuration, avec le PDG Lynn Stockwell demandant l'approbation du tribunal pour l'Accord de Sécurité de Restructuration RSA. Le plan garantit le paiement intégral aux créanciers tout en protégeant les actionnaires existants contre la dilution.
Stockwell, qui gère plusieurs Sociétés d'Acquisition à But Spécial DMAA cotées au NASDAQ, vise à lever plus de 2 milliards de dollars pour des acquisitions pharmaceutiques. La stratégie de l'entreprise se concentre sur le fait de devenir un pionnier dans la production aux États-Unis de substances contrôlées légales à base de plantes à des fins médicales, visant un marché adressable de 100 milliards de dollars.
Le plan d'affaires comprend un investissement de 3,5 milliards de dollars pour des méga-fermes conformes à la DEA et à la FDA, soutenu par des garanties de prêts fédéraux pour les propriétaires/exploitants. Les flux de revenus proviendront de contrats d'approvisionnement en substances contrôlées et du programme d'investissement BGXX EB-5, qui pourrait générer des capitaux grâce à des investissements de 800 000 dollars de la part de demandeurs qualifiés cherchant des cartes vertes américaines.
Bright Green (OTC: BGXX) hat wichtige Schritte in seinem Restrukturierungsplan angekündigt, wobei CEO Lynn Stockwell die Genehmigung des Gerichts für das RSA Restrukturierungs-Sicherheitsabkommen beantragt hat. Der Plan gewährleistet die vollständige Zahlung an die Gläubiger und schützt gleichzeitig die bestehenden Aktionäre vor einer Verwässerung.
Stockwell, der mehrere an der NASDAQ notierte DMAA-Sonderzweckgesellschaften leitet, plant, über 2 Milliarden Dollar für pharmazeutische Übernahmen zu sammeln. Die Strategie des Unternehmens konzentriert sich darauf, ein Pionier in der US-amerikanischen Produktion von pflanzenbasierten, legalen kontrollierten Substanzen zu medizinischen Zwecken zu werden, mit einem ansprechbaren Markt von 100 Milliarden Dollar.
Der Geschäftsplan umfasst eine Investition von 3,5 Milliarden Dollar in DEA- und FDA-konforme Mega-Farmen, unterstützt durch staatliche Darlehensgarantien für Eigentümer/Betreiber. Die Einnahmequellen werden aus Verträgen zur Lieferung von kontrollierten Substanzen und dem BGXX EB-5-Investitionsprogramm stammen, das Kapital durch Investitionen von 800.000 Dollar von qualifizierten Antragstellern generieren könnte, die US-Greencards anstreben.
- New equity funding to pay all creditors in full
- No shareholder dilution in restructuring plan
- Access to $2 billion funding potential through DMAA SPACs
- Federal loan guarantees available for facility development
- Potential revenue from EB-5 program ($800,000 per qualified investor)
- Protected market position with tariffs and supply contracts
- Company currently under restructuring/reorganization
- Revenue streams still in planning phase, not yet operational
- Significant capital requirements ($3.5 billion) for facility development
- Execution dependent on court approval of restructuring plan
FORT LAUDERDALE, FLORIDA, March 21, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXX) (“Bright Green” or the “Company”) announced that on March 17, 2025, on behalf of the Company, Lynn Stockwell has asked the court to approve the “RSA” Restructuring Security Agreement, Disclosure Statement and Plan. The highlights of the Plan and Disclosure will provide new equity for the company to pay all creditors with approved claims in full, in addition the Company equity shareholders will retain their interests in the Company and are unimpaired with no dilution.
Lynn Stockwell, the new Chief Executive Officer and Chairman of the Board of Directors of Bright Green Corporation, is also the CEO, Chair and sponsors and manages other NASDAQ listed corporations under the DMAA label, a series of Special Purpose Acquisition Corporations with plans to raise a combined total of over
Stockwell said, “I have reset the course for Bright Green to become the first mover in the production of plant based legal Controlled Substances for medical purpose establishing a reliable U.S. domiciled API supply chain for the pharmaceutical industry and completing the circle of end-to-end prescription drug manufacturing and home delivery.”
The plant based controlled substances that Bright Green Corporation, through research has the knowledge and expertise to produce and manufacture these Controlled Substances that have never been legally produced commercially in the United States. The critical API supply is imported from countries where diversion and quality controls are not a priority or in the best interests of the United States for their national prescription drug requirements.
Lynn Stockwell continues, “this new federal administration is actively positioning Bright Green to participate in the production, drug manufacturing and prescription drug delivery back to the United States. This creates an opportunity for Bright Green where the drugs purchased in the United States has a total addressable market of more than
With tariffs protecting this new American industry and supply contracts the company will move forward to implement its planned owner/operator operations for a
The Company’s planned revenue is from supply contracts to produce controlled substances and the BGXX EB-5 investment program, the
The Company believes that the timing for both revenue streams will create an opportunity to reset Bright Green Corporation and prepare for the future.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management as of such date. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” “shall” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. Such forward looking statements include, but are not limited to, the ability of the Company to implement the Plan and raise funds under the Company’s EB-5 program, the impact that new officers, directors and employees may have on the Company and the Company’s business and results of operations. The Company’s actual results could differ materially from those stated or implied
Source:
Bright Green Corporation
401 E Las Olas Blvd #1400
Fort Lauderdale, Florida 33301
(833) 658-1799
FAQ
What is the total investment planned for Bright Green's (BGXX) production facilities?
How much can investors contribute through BGXX's EB-5 program?
What is the market size targeted by Bright Green (BGXX) for controlled substances?
How does Bright Green's (BGXX) restructuring plan affect current shareholders?
What is the main business focus of Bright Green (BGXX) under the new restructuring plan?
